Odonate Therapeutics Inc (OQ:ODT)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 4747 Executive Dr Ste 510
SAN DIEGO CA 92121-3100
Tel: N/A
Website: https://www.odonate.com
IR: See website
Key People
kevin C. Tang
Chairman of the Board, Chief Executive Officer
Michael S. Hearne
Chief Financial Officer
John G. Lemkey
Chief Operating Officer
Joseph P. O'Connell
Chief Medical Officer
Business Overview
Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).
Financial Overview
For the three months ended 31 March 2020, Odonate Therapeutics Inc revenues was not reported. Net loss increased 5% to $30.2M. Higher net loss reflects Research and development increase of 6% to $25.6M (expense), General and administrative increase of 20% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.16 to -$0.99.
Employees: 134 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,095M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$116.12M as of Mar 31, 2020
Net annual income (TTM): -$113.34M as of Mar 31, 2020
Free cash flow (TTM): -$97.52M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 32,109,850 as of May 8, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization